Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice

Manuel Monreal

doi:10.1055/s-0038-1675241

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(11): 1850-1851
DOI: 10.1055/s-0038-1675241

Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice

Authors

Manuel Monreal

¹Hospital Universitari Germans Trias I Pujol, Badalona, Spain

Abstract

Full Text

References

References
1 Schulman S, Ageno W, Konstantinides SV. Venous thromboembolism: past, present and future. Thromb Haemost 2017; 117 (07) 1219-1229
2 Schulman S, Singer D, Ageno W, Casella IB, Desch M, Goldhaber SZ. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost 2017; 117 (07) 1317-1325
3 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: Chest Guideline and Expert Panel Report. Chest 2016; 149 (02) 315-352
4 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352
5 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
6 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
7 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
8 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
9 Gómez-Outes A, Lecumberri R, Suárez-Gea ML, Terleira-Fernández AI, Monreal M, Vargas-Castrillón E. Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: A systematic review. J Cardiovasc Pharmacol Ther 2015; 20 (05) 490-500
10 Bleker SM, Brekelmans MPA. , Eerenberg ES, et al. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. Thromb Haemost 2017; 117 (10) 1944-1951
11 Moustafa F, Pesavento R, di Micco P. , et al; RIETE Investigators. Real-life use of anticoagulants in venous thromboembolism with focus on patients with exclusion criteria for direct oral anticoagulants. Clin Pharmacol Ther 2018; 103 (04) 684-691
12 Weycker D, Li X, Wygant GT. , et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in US clinical practice. Thromb Haemost 2018; 118 (11)
13 Trujillo-Santos J, Di Micco P, Dentali F. , et al; RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 2017; 117 (02) 382-389
14 Cohen AT, Gitt AK, Bauersachs R. , et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost 2017; 117 (07) 1326-1337
15 Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (08) 1673-1676